Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis

Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis

IntroductionNon-small cell lung cancer (NSCLC) constitutes approximately 80–85% of cancer-related fatalities globally, and direct and indirect comparisons of various therapies for NSCLC are lacking. In this study, we aimed to compare the efficacy and safety of immune checkpoint inhibitors (ICIs) in...

Full description

Bibliographic Details
Main Authors: Lin Zhu, Wenjuan He, Cunlei Xie, Yang Shu, Chunxia Zhang, Yawen Zhu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Immunology
Subjects:
treatment strategy
immunotherapy
overall survival
progression-free survival
adverse events
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1512468/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1512468/full

Similar Items